GPT and Hepatic steatosis: After 24 weeks of therapy, changes in hepatic steatosis were assessed using MRI-PDFF, which revealed a significant decrease of 7.54% (p < 0.0001) in the pioglitazone group. Significant decrease in AST, ALT, TGs, and a significant increase in HDL were seen